. Наслов: Тространи панел биомаркера системске упале, имунолошке активације и тубуларне повреде (IL-6, suPAR, KIM-1) предвиђа морталитет и кардиоваскуларне исходе код завршне фазе бубрежне болести

Тространи биомаркерски панел системске упале, имунолошке активације и тубуларне по

  • Tong Li 1Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, 518033 Shenzhen city, Guangdong province, China
DOI: https://doi.org/10.5937/jomb0-63251
Ključne reči: End-stage renal disease, Hemodialysis, Biomarkers, Interleukin-6, Soluble urokinase plasminogen activator receptor, Kidney Injury Molecule-1, Prognosis, Cardiovascular disease.

Sažetak


-

Reference

1. Sarnak MJ, Amann K, Bangalore S, et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;74(14):1823-1838.
2. Carrero JJ, Stenvinkel P, Cuppari L, et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr. 2013;23(2):77-90.
3. Zoccali C, Vanholder R, Massy ZA, et al. The systemic nature of CKD. Nat Rev Nephrol. 2017;13(6):344-358.
4. Gupta J, Mitra N, Kanetsky PA, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012;7(12):1938-1946.
5. Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circ Res. 2021;128(11):1728-1746.
6. Hayek SS, Sever S, Ko YA, e
Objavljeno
2026/02/24
Broj časopisa
Ahead of print
Rubrika
Original paper

Sva prava zadržana (c) 2026 Tong Li

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.